一种混合多式机器学习模型用于检测阿尔茨海默氏症
Jinhua Sheng1, Qian Zhang2, Qiao Zhang3
1School of Computer Science and Technology, Hangzhou Dianzi University, Hangzhou, Zhejiang, 310018, China; Key Laboratory of Intelligent Image Analysis for Sensory and Cognitive Health, Ministry of Industry and Information Technology of China, Hangzhou, Zhejiang, 310018, China.
Computers in biology and medicine
|February 7, 2024
概括
将磁共振成像 (MRI),正子发射断层扫描 (PET) 和脑脊液 (CSF) 生物标志物与机器学习相结合,可显著改善阿尔茨海默病 (AD) 诊断. 这种多式模式的方法实现了99.2%的准确性,优于单式模式的方法.
科学领域:
- 神经成像和机器学习用于神经退行性疾病.
背景情况:
- 单个神经成像模式对准确的阿尔茨海默病 (AD) 诊断有局限性.
- 从多个来源整合互补的生物标志物可以提高诊断性能.
- 多模式数据融合为改善AD的特征提供了一个有希望的途径.
研究的目的:
- 开发和评估一个多式联机机器学习框架,以提高阿尔茨海默病的诊断.
- 整合磁共振成像 (MRI),正子发射断层扫描 (PET) 和脑脊液 (CSF) 数据.
- 用一种新的混合优化和分类算法来进行特征选择和诊断.
主要方法:
- 提出了一个多式机器学习框架,将MRI,PET和CSF数据结合起来.
- 开发了一种增强的哈里斯·霍克斯优化 (ILHHO) 算法用于特征选择和内核极端学习机器 (KELM) 用于分类.
- 评估了来自阿尔茨海默病神经成像计划 (ADNI) 数据集的202个受试者的ILHHO-KELM模型.
主要成果:
- 与其他元启发式算法相比,ILHHO算法展示了优越的优化性能.
- 多模式方法 (MRI + PET + CSF) 在区分AD与正常对照 (NC) 中达到99.2%的准确性.
- 多模式分类显著优于单模式诊断准确性.
- 区分性特征分析揭示了MRI和PET的补充信息,突出了神经退行模式.
结论:
- 多模式数据融合,整合MRI,PET和CSF,显著提高了阿尔茨海默病的诊断准确度.
- 协同的ILHHO-KELM模型有效地提取敏感的成像特征用于AD检测.
- 对辅助生物标志物应用的高级特征学习技术对于提高AD诊断至关重要.
相关概念视频
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193


